Potential impacts of GLP-1 drugs should be considered as key risks to Resmed investment thesis. However, the likely impact is overstated, or over-priced into the share price. Resmed is trading at 18 times their FY25 forecast compared to the 10-year average of 28 times.
Potential impacts of GLP-1 drugs should be considered as key...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.78 |
Change
-0.320(0.97%) |
Mkt cap ! $20.91B | |||
| Open | High | Low | Value | Volume |
| $32.74 | $33.07 | $32.74 | $34.25M | 1.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1267 | $32.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.82 | 2077 | 2 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.87 |
Change
-0.320 ( 0.67 %) |
||||
| Open | High | Low | Volume | ||
| $32.77 | $33.07 | $32.77 | 531228 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| RMD (ASX) Chart |